**SUPPLEMENTARY TABLES**

**Supplementary Table S1. The pharmacokinetic profile of bexmarilimab.** Bexmarilimab was administered as a single intravenous dose to cynomolgus monkeys (n(male)=3/dosing group; n(female)=3/dosing group).

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Pharmacokinetic parameter (mean, CV(%))** | | | | | |
|  | **Dose**  **(mg/kg)** | **C0**  **(μg/mL)** | **AUC∞**  **(hr•μg/mL)** | **T1/2,z**  **(h)** | **CL**  **(mL/h/kg)** | **Vss**  **(mL/kg)** | |
| Males | 3 | 68.9 (9.33) | 732 (14.6) | 12.5 (49.2) | 4.16 (15.8) | 28.7 (7.39) | |
|  | 30 | 721 (7.86) | 23,500 (6.22) | 10.7 (41.9) | 1.28 (6.19) | 40.4 (10.9) | |
|  | 100 | 2850 (12.0) | 154,000 (14.2) | 25.1 (24.9) | 0.657 (13.3) | 37.7 (2.81) | |
|  |  |  |  |  |  |  | |
| Females | 3 | 65.2 (11.8) | 624 (13.8) | 24.3 (26.2) | 4.87 (13.8) | 31.0 (8.77) | |
|  | 30 | 741 (15.0) | 17,900 (13.3) | 16.9 (67.6) | 1.70 (12.3) | 37.2 (1.44) | |
|  | 100 | 2660 (8.25) | 134,000 (15.4) | 22.8 (34.7) | 0.757 (14.1) | 38.8 (11.6) | |

C0, back extrapolated concentration at time zero; AUC∞, area under the curve extrapolated to infinity; T1/2,z, apparent terminal half-life; CL, total clearance; Vss, steady-state volume of distribution.